Memantine mediates astrocytic activity in response to excitotoxicity induced by PP2A inhibition.

Reduced activity of protein phosphatase 2 A (PP2A) is a common feature in Alzheimer's disease (AD) and non-AD tauopathies. The administration of okadaic acid (OKA), a potent PP2A and PP1 inhibitor, is a common research tool for inducing AD-like alterations such as tau hyperphosphorylation and cognitive decline. Recently, we showed that OKA increases cerebrospinal fluid (CSF) glutamate levels, which was strongly correlated with cognitive decline. Also, we demonstrated that memantine (MN), a glutamatergic NMDAR channel blocker, was capable of preventing the increase in CSF glutamate levels and cognitive decline. Here, we aimed to analyze whether the protective effects of MN involve intrinsic astrocytic properties, particularly related to glutamate uptake and astrocytic reactivity - indexed by the expression of S100B and glial fibrillary acidic protein (GFAP). Rats received intraperitoneal injections of MN or saline over 3 consecutive days before receiving intrahippocampal infusion of OKA or saline. Afterward, they were submitted to behavioral tasks and then, euthanatized for neurochemical analysis. Here, we showed that the neuroprotective effects of MN in response to OKA neurotoxicity involve astrocytic activation. MN decreased glutamate uptake in the hippocampus and increased the release of S100B protein in the CSF in response to OKA neurotoxicity, which indicates a possible neurons-astrocyte coupling protective mechanism. These findings shed light on astrocytes as potential targets for treating neurological disorders associated with decreased PP2A activity.